Cover Image
市場調查報告書

全球癌症疫苗市場與開發平台疫苗分析

Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020

出版商 iGate Research Pvt Ltd 商品編碼 360467
出版日期 內容資訊 英文 213 Pages
訂單完成後即時交付
價格
Back to Top
全球癌症疫苗市場與開發平台疫苗分析 Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
出版日期: 2015年11月16日 內容資訊: 英文 213 Pages
簡介

本報告提供全球癌症疫苗市場相關調查分析,各地區市場,產業的主要交易、資金籌措,開發中產品的組合,各企業的癌症疫苗開發中產品,推動市場要素,課題等系統性資訊。

第1章 摘要整理

第2章 全球癌症疫苗市場與預測

  • 全球預防用癌症疫苗市場與預測
  • 全球治療用癌症疫苗市場與預測

第3章 全球癌症疫苗市場佔有率與預測

  • 全球癌症疫苗市場佔有率:各類型
  • 全球癌症疫苗市場:企業佔有率分析
  • 癌症疫苗市場:地區佔有率分析

第4章 全球預防用癌症疫苗市場與預測

  • Gardasil的銷售額與預測
  • Cervarix的銷售額與預測

第5章 全球治療用癌症疫苗市場與預測

  • Provenge的銷售額與預測

第6章 癌症疫苗市場:地區分析

  • 美國
  • 歐洲
  • 亞洲

第7章 全球癌症疫苗市場:主要交易

第8章 全球癌症疫苗:資金籌措

第9章 全球癌症疫苗市場:產品研發線分析

  • Prostvac
  • Neuvax
  • Rindopepimut
  • MVax
  • DCVax-L
  • ProstAtak
  • Talimogene Laherparepvec
  • IMA901
  • Imprime PGG
  • OncoVAX
  • Lucanix
  • DCVAC/PCa

第10章 企業的癌症疫苗:開發平台分析

  • Aduro Biotech
  • Advantagene
  • Advaxis
  • Agenus
  • AlphaVax
  • Altor BioScience
  • Argos Therapeutics
  • AVAX Technologies
  • Bavarian Nordic
  • Biothera
  • Celldex Therapeutics
  • CureVac
  • Galena Biopharma
  • Genexine
  • GlobeImmune
  • Gradalis
  • Heat Biologics
  • Immatics
  • ImmunoCellular Therapeutics
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • Juvaris Biotherapeutics
  • NewLink Genetics
  • Northwest Biotherapeutics
  • NovaRx
  • OncoThyreon
  • Oncovir
  • Oxford BioMedica
  • Prima BioMed
  • Sotio
  • Transgene
  • Ubivac
  • Vaccinogen
  • Vaxon Biotech

第11章 全球癌症疫苗市場:推動因素

第12章 全球癌症疫苗市場:課題

圖表

目錄

The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease.

The prophylactic vaccines currently available in the market include Merck's Gardasil and GSK's Cervarix while the only therapeutic vaccine in the market is Dendreon's Provenge. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period.

In the cancer vaccines market, Merck is the clear leader and is expected to maintain its dominancy over a longer period of time. Dendreon Corporation is the second leading player in Cancer vaccines market accounting for XX% market share in 2014. It is predicted that GSK will account for single digit share of the cancer vaccine market by 2020.

Global Cancer Vaccines Market - Regional Analysis: The United States is the largest regional market for cancer vaccines. United States accounted for XX% share of the global cancer vaccines market in 2014. The Asian region is the second leading market for cancer vaccines. The European region cancer vaccines market share is anticipated to increase from XX% in 2014 to XX% by the year 2020.

iGATE Research report titled “Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020” is a 213 page report with 26 Figures and 25 Tables. This report analyses the Global Cancer Vaccines Market, Regional Cancer Vaccines Market, Major Deals and Funding in Cancer Vaccines Industry, Cancer Vaccines Pipeline Products Portfolio, Company Wise Cancer Vaccines Pipeline Products and the driving factors and challenges for the Cancer Vaccines Market.

The Cancer Vaccines Market studied in the report covers the following 7 points:

  • 1. Global - Prophylactic Cancer Vaccines Market to 2020
    • Gardasil
    • Cervarix
  • 2. Global - Therapeutic Cancer Vaccines Market to 2020
    • Provenge
  • 3. Cancer Vaccines Market - Regional Analysis to 2020
    • United States - Cancer Vaccines Market
    • Europe - Cancer Vaccines Market
    • Asia - Cancer Vaccines Market
  • 4. Global Cancer Vaccines Market - Major Deals
  • 5. Global Cancer Vaccines - Funding
  • 6. Global Cancer Vaccines Market - Pipeline Portfolio Analysis
  • 7. Company Cancer Vaccines - Pipeline Analysis

The 12 Cancer Vaccines Pipeline Portfolio covered in the report are as follows

  • 1. Prostvac
  • 2. Neuvax
  • 3. Rindopepimut
  • 4. MVax
  • 5. DCVax-L
  • 6. ProstAtak
  • 7. Talimogene Laherparepvec
  • 8. IMA901
  • 9. Imprime PGG
  • 10. OncoVAX
  • 11. Lucanix
  • 12. DCVAC/PCa

The 34 Companies Pipeline Cancer Vaccines covered in the reports are as follows:

  • 1. Aduro Biotech
  • 2. Advantagene
  • 3. Advaxis
  • 4. Agenus
  • 5. AlphaVax
  • 6. Altor BioScience
  • 7. Argos Therapeutics
  • 8. AVAX Technologies
  • 9. Bavarian Nordic
  • 10. Biothera
  • 11. Celldex Therapeutics
  • 12. CureVac
  • 13. Galena Biopharma
  • 14. Genexine
  • 15. GlobeImmune
  • 16. Gradalis
  • 17. Heat Biologics
  • 18. Immatics
  • 19. ImmunoCellular Therapeutics
  • 20. Inovio Pharmaceuticals
  • 21. ISA Pharmaceuticals
  • 22. Juvaris Biotherapeutics
  • 23. NewLink Genetics
  • 24. Northwest Biotherapeutics
  • 25. NovaRx
  • 26. OncoThyreon
  • 27. Oncovir
  • 28. Oxford BioMedica
  • 29. Prima BioMed
  • 30. Sotio
  • 31. Transgene
  • 32. Ubivac
  • 33. Vaccinogen
  • 34. Vaxon Biotech

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Global - Cancer Vaccines Market and Forecast to 2020

  • 2.1 Global - Prophylactic Cancer Vaccines Market and Forecast to 2020
  • 2.2 Global - Therapeutic Cancer Vaccines Market and Forecast to 2020

3. Global - Cancer Vaccines Market Share and Forecast to 2020

  • 3.1 Global Cancer Vaccines Market Share - By Type
  • 3.2 Global Cancer Vaccines Market - Company Share Analysis
  • 3.3 Cancer Vaccines Market - Regional Share Analysis

4. Global - Prophylactic Cancer Vaccines Market and Forecast to 2020

  • 4.1 Gardasil Sales and Forecast to 2020
  • 4.2 Cervarix Sales and Forecast to 2020

5. Global - Therapeutics Cancer Vaccines Market and Forecast to 2020

  • 5.1 Provenge Sales and Forecast to 2020

6. Cancer Vaccines Market - Regional Analysis

  • 6.1 United States - Cancer Vaccines Market and Forecast to 2020
  • 6.2 Europe - Cancer Vaccines Market and Forecast to 2020
  • 6.3 Asia - Cancer Vaccines Market and Forecast to 2020

7. Global Cancer Vaccines Market - Major Deals

8. Global Cancer Vaccines - Funding

9. Global Cancer Vaccines Market - Pipeline Portfolio Analysis

  • 9.1 Prostvac
  • 9.2 Neuvax
  • 9.3 Rindopepimut
  • 9.4 MVax
  • 9.5 DCVax-L
  • 9.6 ProstAtak
  • 9.7 Talimogene Laherparepvec
  • 9.8 IMA901
  • 9.9 Imprime PGG
  • 9.10 OncoVAX
  • 9.11 Lucanix
  • 9.12 DCVAC/PCa

10. Company Cancer Vaccines - Pipeline Analysis

  • 10.1 Aduro Biotech
  • 10.2 Advantagene
  • 10.3 Advaxis
  • 10.4 Agenus
  • 10.5 AlphaVax
  • 10.6 Altor BioScience
  • 10.7 Argos Therapeutics
  • 10.8 AVAX Technologies
  • 10.9 Bavarian Nordic
  • 10.10 Biothera
  • 10.11 Celldex Therapeutics
  • 10.12 CureVac
  • 10.13 Galena Biopharma
  • 10.14 Genexine
  • 10.15 GlobeImmune
  • 10.16 Gradalis
  • 10.17 Heat Biologics
  • 10.18 Immatics
  • 10.19 ImmunoCellular Therapeutics
  • 10.20 Inovio Pharmaceuticals
  • 10.21 ISA Pharmaceuticals
  • 10.22 Juvaris Biotherapeutics
  • 10.23 NewLink Genetics
  • 10.24 Northwest Biotherapeutics
  • 10.25 NovaRx
  • 10.26 OncoThyreon
  • 10.27 Oncovir
  • 10.28 Oxford BioMedica
  • 10.29 Prima BioMed
  • 10.30 Sotio
  • 10.31 Transgene
  • 10.32 Ubivac
  • 10.33 Vaccinogen
  • 10.34 Vaxon Biotech

11. Global Cancer Vaccines Market - Driving Factors

  • 11.1 Increasing Incidence of Cancer
  • 11.2 GAVI Model Fuelling Vaccine Manufacturers
    • 11.2.1 The Partnership Model
    • 11.2.2 The Business Model
  • 11.3 Global Immunization Vision and Strategy (GIVS)
  • 11.4 Growing Vaccine Availability in United States
  • 11.5 The Vaccine Injury Compensation Program
  • 11.6 The Vaccine Safety Data link Project
  • 11.7 Transformation of Vaccine Technologies
  • 11.8 Global Vaccine Action Plan by WHO (2011 - 2020)
  • 11.9 Continuous Focus on Effective Communication Strategies

12. Global Cancer Vaccines Market - Challenges

  • 12.1 Hurdles to Optimal use of Licensed Vaccines
    • 12.1.1 Technical Obstacles
    • 12.1.2 Economic obstacles
    • 12.1.3 Cultural Obstacles
  • 12.2 Shortening the Timeline for Vaccine Development
  • 12.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
    • 12.3.1 Legal Obstacles
    • 12.3.2 General Technical Barriers
    • 12.3.3 Economic Barriers
    • 12.3.4 Regulatory Barriers
  • 12.4 Obstacles in Vaccine Research and Development
  • 12.5 Barriers to New Entrants in the Vaccines Market

List of Figures:

  • Figure 2-1: Global - Cancer Vaccines Market (Million US$), 2007 - 2014
  • Figure 2-2: Global - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 2-3: Global - Prophylactic Cancer Vaccines Market (Million US$), 2007 - 2014
  • Figure 2-4: Global - Forecast for Prophylactic Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 2-5: Global - Therapeutic Cancer Vaccines Market (Million US$), 2011 - 2014
  • Figure 2-6: Global - Forecast for Therapeutic Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 3-1: Global - Cancer Vaccines Market Share (Percent), 2011 - 2014
  • Figure 3-2: Global - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
  • Figure 3-3: By Company - Cancer Vaccines Market Share (Percent), 2011 - 2014
  • Figure 3-4: By Company - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
  • Figure 3-5: By Region - Cancer Vaccines Market Share (Percent), 2010 - 2014
  • Figure 3-6: By Region - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
  • Figure 4-1: Global - Gardasil Vaccines Sales (Million US$), 2007 - 2014
  • Figure 4-2: Global - Forecast for Gardasil Vaccines Sales (Million US$), 2015 - 2020
  • Figure 4-3: Global - Cervarix Vaccines Sales (Million US$), 2007 - 2014
  • Figure 4-4: Global - Forecast for Cervarix Vaccines Sales (Million US$), 2015 - 2020
  • Figure 5-1: Global - Provenge Vaccines Sales (Million US$), 2011 - 2014
  • Figure 5-2: Global - Forecast for Provenge Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-1: United States - Cancer Vaccines Market (Million US$), 2010 - 2014
  • Figure 6-2: United States - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 6-3: Europe - Cancer Vaccines Market (Million US$), 2010 - 2014
  • Figure 6-4: Europe - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 6-5: Asia - Cancer Vaccines Market (Million US$), 2010 - 2014
  • Figure 6-6: Asia - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
  • Figure 11-1: Global - Estimated Number of Cancer Incidence Cases (Number), 2009 - 2015
  • Figure 11-2: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

List of Tables:

  • Table 9-1: NovaRx - Clinical Development Pipeline
  • Table 10-1: AlphaVax - Clinical Development Pipeline
  • Table 10-2: Altor BioScience - Clinical Development Pipeline
  • Table 10-3: Argos Therapeutics - Clinical Development Pipeline
  • Table 10-4: AVAX Technologies - Clinical Development Pipeline
  • Table 10-5: Biothera - Clinical Development Pipeline
  • Table 10-6: Celldex Therapeutics - Clinical Development Pipeline
  • Table 10-7: CureVac - Clinical Development Pipeline
  • Table 10-8: Genexine - Clinical Development Pipeline
  • Table 10-9: GlobeImmune - Clinical Development Pipeline
  • Table 10-10: Gradalis - Clinical Development Pipeline
  • Table 10-11: Heat Biologics - Clinical Development Pipeline
  • Table 10-12: ISA Pharmaceuticals - Clinical Development Pipeline
  • Table 10-13: ISA101-CervISA - Clinical Study Analysis
  • Table 10-14: NewLink Genetics - Clinical Development Pipeline
  • Table 10-15: Northwest Biotherapeutics - Clinical Development Pipeline
  • Table 10-16: NovaRx - Clinical Development Pipeline
  • Table 10-17: Sotio - Clinical Development Pipeline
  • Table 10 -18: Transgene - Clinical Development Pipeline
  • Table 10-19: UbiVac - Clinical Development Pipeline
  • Table 10-20: Vaccinogen - ACTIVE Clinical Trial Analysis
  • Table 10-21: Vaxon Biotech - Clinical Developmet Pipeline
  • Table 11-1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
  • Table 11-2: Global Goal-Level Indicators, 2015 and 2020
  • Table 11-3: Improvement Strategies or Requirements - the Joint Commission and the Projects Collaborating Organizations
Back to Top